Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Petro Metad go for broke with 6-well fully funded programme
EXCLUSIVE: Rockhopper #RKE tops Malcy's 2018 Interims Bucket List gain


Physiomics Share Chat (PYC)



Share Price: 3.85Bid: 3.80Ask: 3.90Change: 0.00 (0.00%)No Movement on Physiomics
Spread: 0.10Spread as %: 2.63%Open: 3.85High: 4.10Low: 3.85Yesterday’s Close: 3.85


Share Discussion for Physiomics


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

bassguy
Posts: 463
Opinion:No Opinion
Price:3.85
RE: ApplegarthLSE...
Fri 16:13
Maybe look in the mirror, your mantra has not changed and I have never seen such a committed attempt at bashing a company...
 
bassguy
Posts: 463
Opinion:No Opinion
Price:3.85
RE: ApplegarthLSE...
Fri 16:12
Maybe look in the mirror, your mantra has not changed and I have never seen such a committed attempt at basng a company...
Strongman
Posts: 966
Opinion:No Opinion
Price:3.95
Chart view
Fri 12:06
Posted on twitter by a well known chartist:

Perched on support of a bullish falling wedge pattern. RSI at 30 and edging towards being oversold

Currently targeting 5.70p wedge resistance, with an extension target of 14.20p

Intermediate resistance points at major MA levels, and gap fill at 6.05p
Strongman
Posts: 966
Opinion:No Opinion
Price:3.95
Sp
Fri 11:55
Sub placing price and £2.6m market cap. Now that seems to be a good price for a position here, so I have taken a few this morning.

I was particularly please reading the last trading update and cash position since placing reloaded our bank accounts.

Good bottom feed here IMO.

'' Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that based on its current unaudited accounts at 20th June, it is trading ahead of market expectations for its full financial year ending 30th June 2018. ''
earthling
Posts: 9,471
Opinion:No Opinion
Price:3.85
RE: ApplegarthLSE...
Thu 17:38
I’m afraid I don’t believe you

You don’t get in profit through averaging down several times

Not based on what the SP had done
Daveeeed
Posts: 559
Premium Chat Member
Opinion:Strong Buy
Price:3.90
RE: THE RAMPERS
Thu 13:57
Good got me some cheap ( imo ) minimum downside here with potentially explosive upside, just requires a little more patience. Was hoping MM’s would drop it tbh
mannnan
Posts: 41,607
Premium Chat Member
Opinion:No Opinion
Price:3.95
THE RAMPERS
Thu 12:48
gone ......left the board empty
surfi
Posts: 244
Opinion:Strong Buy
Price:3.95
strong buy
Tue 15:50
Merck specialise in inventing medicines & vaccines! its a german company.

http://www.merck.com/index.html

this client has been working with PYC since 2012 and from november signed a contract worth approx £500k,The Agreement envisages a multi-year relationship! strong chance of PYC getting a multi year contract with Merck! SP went to 32p on the back of this 1 year deal with Merck so a multi-year agreement will send the sp back over 20p imo
Daveavt
Posts: 3,622
Opinion:No Opinion
Price:4.05
RE: Strong buy
Tue 00:14
You could have just reworded that existing customer is going to keep being a customer. There is no 'contract' in that meaning of the term, as it says no guaranteed amount more than that and no set term. So they are not tied to this at all. Also Merck is the largest supplies of LCD crystals in the world and industrial chemicals supplier, so the claim of their turnover is a bit irrelevant to this sector.
surfi
Posts: 244
Opinion:Strong Buy
Price:4.10
investment case
8 Jul '18
Physiomics ready to build on Merck Serono landmark
14 May 2018
Physiomics' share price surged on a �500,000 contract for its virtual tumour software with Merck KgaA.
cancer
* Virtual Tumour can be adapted for all forms of cancer
A 90-degree spike on a share price graph is rare and almost always indicates very good news.

For Physiomics Plc its share price surge was sparked by a �500,000 contract for its virtual tumour software with Merck KgaA.

* Physiomics PLC: Personalised medicines will build on momentum from recent pharma deals
To clarify, this is not the US pharma supermajor Merck but an unrelated German firm also known as Merck Serono.

* This Merck though still has 50,000 staff, a net worth in the billions and is also a cancer drug developer so it�s not hard to spot why investors were so enthusiastic.

Merck Serono a big name
Not only does the deal generate a significant amount of revenue, but interestingly Merck Serono also allowed its name to be linked with the contract.

In the secretive world of pharma/biotech drug development that is unusual says Jim Millen, Physiomics� chief executive, who sees it as a clear validation of the progress made by the company since he took charge two years ago.

The German company had been working with Physiomics for some time but the contract was a significant step-up in scale and might herald further even deals not only with Merck Serono but other pharmas.

Cancer simulation technology
As the name implies, Virtual Tumour is a simulation programme. The software predicts the effect of different combinations of drugs on whatever type of cancer a pharma might be researching.

Millen says Virtual Tumour helps the pharma decide the optimum combinations of drugs for a specific cancer along with other important elements such as dose sizes and how it should be administered.

It gives a head start when designing development programmes and helps to avoid costly failures especially in clinical trials.

As new cancer drugs can cost up to US$1bn, involve 10 years of work and still fail right at the end of the process, anything a pharma can do to increase the probability of success is worth something, he says.

VT very adaptable
So far, Virtual Tumour has been used to model 40-50 types of the disease but its adaptability means it has the potential to be used across all areas of oncology, says Millen.

Since the Merck KgaA deal, Physiomics has also picked up contracts from two more major pharma groups and a smaller UK biotech, though none of these have been named.

A second grant has also been made to the company from the government-backed tech innovation body Innovate UK.
surfi
Posts: 244
Opinion:Strong Buy
Price:4.10
Strong buy
8 Jul '18
‪#PYC has a contract with Merck (german pharma) worth €500,000 minimum for first 12 months. This contract was signed last year. Pyc has been working with Merck for 5 years. The agreement between the 2 envisages a multi year relationship. So imo this contract will be ongoing and increase. Merck had annual revenue of $40.12 billion in 2017. This is just one big pharma client with others also on board. This is why i believe pyc is in a really good position with there cancer tumour technology in an industry worth billions. ‬low market cap of £2.4m means there is huge upside
Daveavt
Posts: 3,622
Opinion:No Opinion
Price:4.20
RE: ApplegarthLSE...
5 Jul '18
'had 8 grand invested but gradually averaged down SIX times until i was in profit, investing a total of 27 grand..'

Why don't you take the responsibility that you got it wrong instead of blaming people who said it exactly how it is, and got it right.

You are still number 2 on the leaderboard of PumpedorDumped. I think you need to step outside of yourself and look in, and see what everyone else sees.
applegarth
Posts: 13,203
Opinion:No Opinion
Price:4.20
RE: ApplegarthLSE...
5 Jul '18
Yes bassguy...i'm out. I was explaining to nomlungu...why. I had to get out, couldn't take the incessant deramping. I had 8 grand invested but gradually averaged down SIX times until i was in profit, investing a total of 27 grand...so sold. It's not PYC just the derampers that bash the share continuously on any rise...had enough, good luck to genuine holders but to the derampers, if ever you get any luck it will be providence gone mad.
nomlungu
Posts: 1,532
Opinion:No Opinion
Price:4.10
RE: Pyc
3 Jul '18
This trade may be a deluded rampers heading for the hills with his / her tail between their legs blaming a conspiracy theory for their loss even though they bought on a spike and now feel the pain of catching a falling knife. Never a rewarding experience.

Good luck to those who believe in the science and the commercial potential here but I fear Alphabet gets there sooner as they have the data, computing power, and the funds.

https://www.google.com/intl/en_us/health/about/
bassguy
Posts: 463
Opinion:No Opinion
Price:4.20
RE: ApplegarthLSE...
2 Jul '18
Apple, you out here? Thought this was one of your shares of the year, what changed? Im on a free ride so hanging on in but feel it's a couple year hold min.
Daveavt
Posts: 3,622
Opinion:No Opinion
Price:4.15
RE: ApplegarthLSE...
2 Jul '18
No, one one has warned me because it's nothing to do with me. But if it stops you ramping the hell out of everything then there is a bonus out of it.
applegarth
Posts: 13,203
Opinion:No Opinion
Price:4.15
RE: ApplegarthLSE...
2 Jul '18
paolo...i think it is Daveavt that has copied my username on advfn...admin have warned him. I am finished with this stock called it a waste of time with so much trolling. I don't keep reporting just filtering...you lot on here i do not wish any luck..ridiculous state of affairs. Just made 15 grand on GGP and another 9 grand on Ukog a far cry from the silly profits you lot gain here...good bye and good riddance, ffs
Daveavt
Posts: 3,622
Opinion:No Opinion
Price:4.20
RE: pyc
2 Jul '18
It's bliss on here without all the endless ramping.
applegarth
Posts: 13,203
Opinion:No Opinion
Price:4.20
RE: ApplegarthLSE...
29 Jun '18
paolo.....not sad just peeved that someone copies me and then posts negative...not in these by the way, managed only just to get my money back....managed a huge buy to average down then sold the lot on small rise...that's the way to do it.....and good riddance to me and good riddance to the host of trolls on here.

Imitation is the best form e.of flattery....lol
applegarth
Posts: 13,203
Opinion:No Opinion
Price:4.50
ApplegarthLSE...
26 Jun '18
Just to let you know...a poster has copied the above (my) username and added LSE at the end and is now in the process of trashing continuously on ADVFN - PSL, LION boards.....it's not me. i don't know if the poster is doing the same elsewhere..but just to let you know. I do believe it is someone that may be banned or suspended with a warning as i have reported a few trolls lately. Who ever it is, he has it in for me. with a passion

If anyone here has an account with ADVFN you have my permission to deny it on my behalf. Also it has been brought to my notice that this poster is also busy on twitter. I never use twitter and i believe most of you know that i am NEVER negative on any stock

ApplegarthLSE........on ADVFN or twitter is not me
surfi
Posts: 244
Opinion:Strong Buy
Price:4.50
Loaded up here
26 Jun '18
imo i feel PYC is in a really good position. After last weeks trading update to confirm income is ahead of market expectation is great vote of confidence. They have big pharma customers on board, website updated and funds already raised for future growth. Could see some massive contracts land in the next 6 months and the sp could be of multiples from current position. Market cap very low.
BoredTeacher
Posts: 185
Opinion:No Opinion
Price:4.50
On the Rise
26 Jun '18
Lets hope it continues to the weekend........
potnak
Posts: 1,280
Opinion:No Opinion
Price:4.20
RE: pyc
25 Jun '18
But will 'they are stating facts' be a valid reason?




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.